LRP5 and neoplasm: The UBE3C-LRP5 fusion protein and the Wnt pathway can be targeted by the FDA-approved anthelminthic drug pyrvinium pamoate, which degrades β-catenin to inactivate the pathway, leading to a reduction in the anchorage-independent growth of cells and tumor volume in mice bearing tumors of fusion overexpression clones.